Payden & Rygel’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.69M | Buy |
309,580
+104,500
| +51% | +$2.78M | 0.67% | 60 |
|
|
2025
Q4 | $5.11M | Buy |
205,080
+204,700
| +53,868% | +$5.16M | 0.35% | 70 |
|
|
2025
Q3 | $10K | Sell |
380
-24,300
| -98% | -$600K | ﹤0.01% | 113 |
|
|
2025
Q2 | $598K | Hold |
24,680
| – | – | 0.05% | 83 |
|
|
2025
Q1 | $625K | Hold |
24,680
| – | – | 0.05% | 90 |
|
|
2024
Q4 | $655K | Sell |
24,680
-289,300
| -92% | -$7.85M | 0.06% | 88 |
|
|
2024
Q3 | $9.09M | Buy |
313,980
+284,000
| +947% | +$8.28M | 0.7% | 62 |
|
|
2024
Q2 | $839K | Sell |
29,980
-240,400
| -89% | -$6.62M | 0.07% | 88 |
|
|
2024
Q1 | $7.5M | Buy |
270,380
+240,400
| +802% | +$6.67M | 0.35% | 77 |
|
|
2023
Q4 | $863K | Hold |
29,980
| – | – | 0.06% | 100 |
|
|
2023
Q3 | $994K | Buy |
29,980
+24,300
| +428% | +$859K | 0.07% | 97 |
|
|
2023
Q2 | $208K | Sell |
5,680
-244,590
| -98% | -$9.52M | 0.01% | 120 |
|
|
2023
Q1 | $10.2M | Sell |
250,270
-243,720
| -49% | -$10.5M | 0.6% | 70 |
|
|
2022
Q4 | $25.3M | Sell |
493,990
-359,500
| -42% | -$17.2M | 1.35% | 31 |
|
|
2022
Q3 | $37.3M | Buy |
853,490
+20,800
| +2% | +$1.01M | 2.18% | 6 |
|
|
2022
Q2 | $43.7M | Buy |
832,690
+126,700
| +18% | +$6.46M | 2.62% | 3 |
|
|
2022
Q1 | $36.5M | Buy |
705,990
+209,520
| +42% | +$10.9M | 1.84% | 13 |
|
|
2021
Q4 | $29.3M | Hold |
496,470
| – | – | 1.36% | 28 |
|
|
2021
Q3 | $21.4M | Hold |
496,470
| – | – | 1.11% | 49 |
|
|
2021
Q2 | $19.4M | Sell |
496,470
-3,100
| -0.6% | -$121K | 0.93% | 66 |
|
|
2021
Q1 | $18.1M | Buy |
499,570
+10,700
| +2% | +$380K | 0.84% | 65 |
|
|
2020
Q4 | $18M | Sell |
488,870
-47,479
| -9% | -$1.74M | 0.92% | 60 |
|
|
2020
Q3 | $18.7M | Buy |
536,349
+23,293
| +5% | +$817K | 1.11% | 48 |
|
|
2020
Q2 | $15.9M | Hold |
513,056
| – | – | 1.01% | 56 |
|
|
2020
Q1 | $15.9M | Sell |
513,056
-391,561
| -43% | -$13.3M | 1.15% | 43 |
|
|
2019
Q4 | $33.6M | Sell |
904,617
-3,899
| -0.4% | -$139K | 2.1% | 17 |
|
|
2019
Q3 | $31M | Sell |
908,516
-23,083
| -2% | -$839K | 2.11% | 18 |
|
|
2019
Q2 | $38.3M | Buy |
931,599
+79,788
| +9% | +$3.17M | 2.62% | 5 |
|
|
2019
Q1 | $34.3M | Sell |
851,811
-316
| -0% | -$12.7K | 2.5% | 7 |
|
|
2018
Q4 | $35.3M | Buy |
852,127
+88,009
| +12% | +$3.65M | 2.85% | 5 |
|
|
2018
Q3 | $31.9M | Sell |
764,118
-18,361
| -2% | -$707K | 2.43% | 5 |
|
|
2018
Q2 | $26.9M | Sell |
782,479
-3,373
| -0.4% | -$115K | 2.12% | 11 |
|
|
2018
Q1 | $26.5M | Buy |
785,852
+200,576
| +34% | +$6.9M | 2.15% | 10 |
|
|
2017
Q4 | $20.1M | Hold |
585,276
| – | – | 1.75% | 17 |
|
|
2017
Q3 | $19.8M | Hold |
585,276
| – | – | 1.97% | 14 |
|
|
2017
Q2 | $18.7M | Buy |
585,276
+13,386
| +2% | +$422K | 1.63% | 20 |
|
|
2017
Q1 | $18.6M | Hold |
571,890
| – | – | 1.69% | 22 |
|
|
2016
Q4 | $17.6M | Buy |
571,890
+36,785
| +7% | +$1.12M | 1.63% | 25 |
|
|
2016
Q3 | $17.2M | Hold |
535,105
| – | – | 1.72% | 26 |
|
|
2016
Q2 | $17.9M | Hold |
535,105
| – | – | 2.03% | 17 |
|
|
2016
Q1 | $15M | Buy |
535,105
+5,749
| +1% | +$164K | 1.83% | 23 |
|
|
2015
Q4 | $16.2M | Sell |
529,356
-56,236
| -10% | -$1.77M | 2.14% | 13 |
|
|
2015
Q3 | $17.5M | Sell |
585,592
-284
| -0% | -$9.11K | 2.51% | 6 |
|
|
2015
Q2 | $18.6M | Hold |
585,876
| – | – | 2.46% | 8 |
|
|
2015
Q1 | $19.3M | Buy |
585,876
+167,016
| +40% | +$5.31M | 2.52% | 5 |
|
|
2014
Q4 | $12.4M | Buy |
418,860
+123,529
| +42% | +$3.54M | 2.37% | 6 |
|
|
2014
Q3 | $8.29M | Sell |
295,331
-11,910
| -4% | -$334K | 1.64% | 23 |
|
|
2014
Q2 | $8.65M | Buy |
307,241
+115,940
| +61% | +$3.3M | 2.19% | 13 |
|
|
2014
Q1 | $5.83M | Buy |
191,301
+1,686
| +0.9% | +$50.3K | 2.27% | 11 |
|
|
2013
Q4 | $5.51M | Hold |
189,615
| – | – | 1.88% | 16 |
|
|
2013
Q3 | $5.17M | Buy |
189,615
+86,955
| +85% | +$2.37M | 1.84% | 14 |
|
|
2013
Q2 | $2.73M | Buy |
+102,660
| New | +$2.84M | 1.07% | 52 |
|
Other funds holding PFE
VCM
VPM
Payden & Rygel's PFE Position: Q1 2026 in Review
Payden & Rygel increased its Pfizer (PFE) stake by 51% in Q1 2026, buying an estimated $2.78M and bringing the position to 309,580 shares worth $8.69M. The position accounts for 0.67% of the portfolio, ranked #60.
Payden & Rygel first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $43.7M in Q2 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Payden & Rygel held 309,580 shares of Pfizer worth $8.69M as of Q1 2026.
- Payden & Rygel bought 104,500 Pfizer shares in Q1 2026, an estimated $2.78M.
- Pfizer made up 0.67% of Payden & Rygel's portfolio in Q1 2026, its #60 holding.
- Payden & Rygel first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Payden & Rygel's Pfizer position peaked at $43.7M in Q2 2022.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Payden & Rygel's 13F filing for Q1 2026, filed 12 May 2026.